This announcement is a separate document:
國藥控股：有關採購及銷售交易的持續關連交易： 建議追認2021年度實際交易金額及 建議修訂2022年度及2023年度年度上限 及 股東特別大會通告
SINOPHARM: CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE PROCUREMENT AND SALES TRANSACTIONS: PROPOSED RATIFICATION OF THE 2021 ACTUAL TRANSACTION AMOUNTS AND PROPOSED REVISION OF THE ANNUAL CAPS FOR 2022 AND 2023 AND NOTICE OF EGM
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.